Clinical trials: Healthy Cohort
Seemingly Healthy, Genetic Predisposition to Disease
Return of Genomic Results and Aggregate Penetrance in Population-Based Cohorts
The PopSeq Project is a prospective cohort study that will develop and implement a genomic return of results (gRoR) process in the Framingham Heart Study (FHS) and Jackson Heart Study (JHS) cohorts and explore associated medical…
- Trial name
- PopSeq (NCT04196374)
- Testing
- Genomic Sequencing
- Where
- 2 sites in United States
- Volunteers
- 7,603 people
- Sponsor
- Brigham and Women's Hospital
Genetic Disease, Nonsense Mutation
Phase 1 Study of ELX-02 in Healthy Adult Subjects
Phase 1 Multiple Ascending Dose Study in Normal Healthy Volunteers
- Trial name
- NCT03309605
- Testing
- ELX-02
- Where
- Belgium
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Eloxx Pharmaceuticals, Inc.
Hyperkalaemia
Study to Assess the Effect of Sodium Zirconium Cyclosilicate on the Pharmacokinetics of Tacrolimus and Cyclosporin in Healthy Subjects
This study will be an open-label, randomised sequence, 2-period, 2-cohort, 2-treatment in each cohort, cross-over study in healthy subjects (males and females of non-childbearing potential), performed at a single study centre.
- Trial name
- NCT04788641
- Testing
- Tacrolimus, Cyclosporin, Sodium Zirconium Cyclosilicate
- Where
- Germany
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy, Atopic Dermatitis
A Study of Crisaborole Ointment 2% in Adult Japanese Healthy Subjects and Adult Japanese Subjects With Mild To Moderate Atopic Dermatitis
This is a Phase 1 parallel-cohort study of crisaborole ointment 2% to evaluate the skin irritation potential in adult Japanese healthy subjects in Cohort 1, and to evaluate the safety, tolerability and PK in adult Japanese…
- Trial name
- NCT03260595
- Testing
- Crisaborole ointment 2%, Vehicle
- Where
- Japan
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Pfizer
HIV Infections
A Food-effect Study of the Pediatric Dispersible Tablet Formulations of TRIUMEQ® and DOVATO® in Healthy Adult Participants
This study will assess the effect of food on the pharmacokinetics (PK) of pediatric formulations of TRIUMEQ (dolutegravir [DTG] 5 milligrams [mg]/abacavir [ABC] 60 mg/lamivudine [3TC] 30 mg) dispersible tablets and DOVATO (DTG 5…
- Trial name
- NCT04827134
- Testing
- TRIUMEQ, DOVATO
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Stress, Psychological
The Impact of 8 Weeks of Digital Meditation Application and Healthy Eating Program on Work Stress and Health Outcomes
The aim of the present study is to test the effects of a digital meditation intervention and/or a healthy eating intervention in a sample of UCSF employees with overweight and obesity (BMI>=25kg/m2) who report mild to moderate…
- Conditions
- Stress, Psychological, Behavioral Symptoms, Sleep
- Trial name
- SFUC+Health (NCT03945214)
- Testing
- Meditation, Healthy Eating, Meditation + healthy eating
- Where
- United States
- Volunteers
- 163 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Breast Cancer, Mammographic Density
Karolinska Interventional Study of Mammograhic Density (Karisma-1)
A feasibility study, randomising to either 10 or 20 mg of tamoxifen. The primary aim is to identify the time to mammographic density change and piloting the procedures.
- Trial name
- Karisma-1 (NCT04079517)
- Testing
- Tamoxifen
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Karolinska Institutet
Healthy, Hepatic Insufficiency
A Study To Describe The Effect Of Impaired Hepatic Function Of The Pharmacokinetics Of Palbociclib
This is a phase 1 study to describe the plasma pharmacokinetics of a single oral 75mg dose of palbociclib administered to healthy volunteers, and subjects with mild, moderate, and severely impaired hepatic function.
- Trial name
- NCT02334800
- Testing
- Palbociclib 75 mg Capsule
- Where
- 2 sites in United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Pfizer
Freeze Dried Plasma in Healthy Volunteers
Ascending Doses of Autologous FDP vs FFP
Assess the safety of single infusions with RePlas FDP product at increasing fixed doses
- Trial name
- FDP (NCT02930226)
- Testing
- Autologous Freeze Dried Plasma (FDP), Fresh Frozen Plasma (FFP)
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Healthy Volunteers
Safety and Pharmacokinetics Study of Redosing EXPAREL in Healthy Volunteers
The purpose of this study is to evaluate the safety and pharmacokinetics of redosing EXPAREL via local subcutaneous infiltration in healthy volunteers.
- Trial name
- NCT02210247
- Testing
- EXPAREL
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Pacira Pharmaceuticals, Inc
Plaque Psoriasis
A First in Human Study to Evaluate Safety, Tolerability, and Pharmacology of PF-06826647 in Healthy Subjects and Subjects With Plaque Psoriasis
This first in human study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PF-06826647 in healthy subjects and subjects with plaque psoriasis.
- Trial name
- NCT03210961
- Testing
- PF-06826647 tablet, PF-06826647 oral suspension
- Where
- United States
- Volunteers
- 109 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy Volunteers
A Drug-Drug Interaction Study to Assess the Pharmacokinetics of DC-806 When Orally Administered Alone, When Coadministered With Itraconazole, and When Coadministered With Carbamazepine in Healthy Adult Participants
The primary objective of this study was to assess the effect of a cytochrome P450 3A4 (CYP3A4) inhibitor (itraconazole) and CYP3A4 inducer (carbamazepine) on the single dose pharmacokinetics (PK) of DC-806 coadministered with…
- Trial name
- NCT05994807
- Testing
- DC-806, Itraconazole, Carbamazepine
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company